Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Canopy Growth Corp T.WEED

Alternate Symbol(s):  T.WEED.DB | CGC

Canopy Growth Corporation is a cannabis company. It delivers innovative products with a focus on premium and mainstream cannabis brands, including Doja, 7ACRES, Tweed, and Deep Space, in addition to category-defining vaporizer technology made in Germany by Storz & Bickel. The principal activities of the Company are the production, distribution and sale of a diverse range of cannabis and cannabinoid-based products for both adult-use and medical purposes under a portfolio of distinct brands in Canada. Its Canada cannabis segment includes the production, distribution, and sale of a range of cannabis, hemp, and cannabis related products in Canada. International markets cannabis segment includes the production, distribution, and sale of a range of cannabis and hemp products internationally. Storz & Bickel segment includes the production, distribution, and sale of vaporizers. This Works segment includes the production, distribution and sale of beauty, skincare, wellness and sleep products.


TSX:WEED - Post by User

Bullboard Posts
Comment by Peytonon Jul 08, 2018 1:26pm
74 Views
Post# 28285264

RE:RE:RE:RE:RE:RE:RE:RE:saveyourselfnow

RE:RE:RE:RE:RE:RE:RE:RE:saveyourselfnow$75 is ridiculous by October. But it certainly isnt for sometime in 2019. 2019 revenues should be somewhere either just below, or just above $1 Billion. Our next big wave of growth will come when this thing starts snowballing globally. It has already begun, but its going to start coming on alot quicker in the next couple years. What I'm most excited for is the clinical trials that are currently ongoing. Once completed, we should have approval for a formulation and a DIN # shortly after. This is when things get the most exciting for me. Ive been invested since 2015/2016, and the one thing that excites me the most is the DIN #'s upcoming for Medical. That will be the final stamp for the upcoming global wave we are about to witness. There is really only 1 company in the world that has situated itself to capture this entire market to its fullest.

55orbust wrote:
saveyourselfnow wrote:
PrZinvesting wrote:
bunch of trolls polluting this forum


Who? Which trolls?

Me? Not trolling - agreeing with other posters who make logical statements and disagreeing with those who pump ridiculous sp projections like $75 by October.
 


Confucius says when you throw a stick into a pack of wolves, the one it hits will cry.


Bullboard Posts